PCM
YMAB

Prelude Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Prelude Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-458
Closed -$10K – 2114
2019
Q2 		$10K Buy
+458
New +$10.5K ﹤0.01% 1404

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Prelude Capital Management's YMAB Position: Q3 2019 in Review

Prelude Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2019, closing a stake of 458 shares — an estimated $10K sold.

Prelude Capital Management first reported a position in YMAB in Q2 2019 and held it in 1 quarter. The position peaked at $10K in Q2 2019. 65 funds tracked by Wall St. Rank hold YMAB as of Q3 2019.

  • Prelude Capital Management reported no remaining Y-mAbs Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Prelude Capital Management sold 458 Y-mAbs Therapeutics shares in Q3 2019, an estimated $10K.
  • Prelude Capital Management first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 1 quarter.
  • Prelude Capital Management's Y-mAbs Therapeutics position peaked at $10K in Q2 2019.
  • 65 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2019.

Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.